- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT05278156
Studio di efficacia, sicurezza e farmacocinetica di CPL500036 (inibitore della PDE10A) in pazienti con schizofrenia
Studio di fase II, in doppio cieco, randomizzato, controllato con placebo, a gruppi paralleli, per esplorare l'efficacia, la sicurezza e la farmacocinetica di CPL500036 (inibitore della PDE10A) in pazienti con esacerbazione acuta della schizofrenia
The purpose of this study is to determine the efficacy, safety, tolerability and pharmacokinetics (PK) properties of CPL500036 compound (PDE10a inhibitor) in patients with an acute exacerbation of schizophrenia after 28 days of administration..
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This is a double-blind, randomized, placebo controlled, parallel group, dose ranging study to explore the efficacy, safety, tolerability and PK of 2 different doses of CPL500036 (phosphodiesterase 10A [PDE10A] inhibitor) in patients with an acute exacerbation of schizophrenia. Approximately 165 patients will be randomized at a 1:1:1 ratio and will be dosed with 20 mg CPL500036, 40 mg CPL500036 or placebo once daily for 28 consecutive days (Day 1 to Day 28). Patients will remain in house for the duration of the Treatment Period. The study will comprise of a Screening Period (that will include a prior Medication Washout Period), a Treatment Period and a Follow-up Period. After discharge from the Clinical Unit, patients will return to the Clinical Unit for 2 once weekly Follow-up Visits. Approximately 30% of the patients (17 patients in each of the 3 treatment groups) will undergo extensive PK sampling during the Treatment Period, and the remaining 70% of the patients will only undergo sparse PK sampling.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Bialystok, Polonia, 15-272
- Uniwersytecki Szpital Kliniczny
-
Bolesławiec, Polonia, 59-700
- Wojewódzki Szpital dla Nerwowo i Psychicznie Chorych
-
Choroszcz, Polonia, 16-070
- Samodzielny Publiczny Psychiatryczny Zakład Opieki Zdrowotnej
-
Gmina Świecie, Polonia, 86-100
- Wojewódzki Szpital dla Psychicznie i Nerwowo Chorych
-
-
-
-
-
Ivano-Frankivsk, Ucraina, 76014
- Ivano-Frankivsk National Medical University, Department of Psychiatry, Narcology and Medical Psychology
-
Kyiv, Ucraina, 04080
- Communal non-profit enterprise "Clinical Hospital "PSYCHIATRY"" of the executive body of the Kyiv City Council (Kyiv City State Administration), Center for Primary Psychotic Episode and Modern Treatment Methods.
-
Kyiv, Ucraina, 08631
- Communal non-commercial enterprise of the Kyiv Regional Council "Regional Psychiatric-Narcological Medical Association", women's department No. 2, men's department No. 10.
-
Lviv, Ucraina, 79017
- Communal non-commercial enterprise of the Lviv Regional Council "Lviv Regional Clinical Psychoneurological Dispensary",
-
Lviv, Ucraina, 79021
- Communal non- commercial enterprise of Lviv Regional Council "Lviv Regional Clinical Psychiatric Hospital",
-
Ternopil, Ucraina, 46001
- Ternopil National Medical University named after I.Y. Gorbachevskiy of the Ministry of Health of Ukraine, Department of Psychiatry, Narcology and Medical Psychology
-
Vinnytsia, Ucraina, 21018
- Vinnytsia National Medical University named after M.I. Pirogov, Department of Psychiatry, Narcology and Psychotherapy with a course of postgraduate education
-
-
-
-
-
Budapest, Ungheria, H-1083
- Department of Psychiatry and Psychotheraapy of Semmelweis University
-
Budapest, Ungheria, H-1085
- Semmelweis University, Faculty of Medicine, Department of Psychiatry and Psychotherapy
-
Győr, Ungheria, H-9024
- Department of Psychiatry, Mental hygiene and Addictology of Petz Aladár County Teaching Hospital
-
Kalocsa, Ungheria, H-6300
- Bács-Kiskun County Teaching Hospital Kalocsa Holy Cross Hospital
-
Szekszárd, Ungheria, H-7100
- Psychiatry Department of Tolna County Balassa Janos Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- The patient has a primary diagnosis of schizophrenia confirmed by clinical interview [SCID-5-CT].
- Male or female patient aged 18 to 65, inclusive, at Screening.
- The patient's with exacerbation of psychotic symptoms
- The patient has a score of 5 or higher in 3 or more items of the following PANSS items at Screening and Baseline
- The patient has a PANSS Total Score of 80 or higher during Screening and on Baseline
- The patient of childbearing potential willing to use acceptable forms of contraception.
- The patient has a score in CGI-S scale of 4 or greater at Screening and on Baseline
- The patient is able to and agrees to remain off prior antipsychotic medication and all excluded medications as outlined in the protocol for the duration of the Treatment Period.
- The patient is able to sign informed consent after receiving information about the trial and has the ability and willingness to comply with the requirements and restrictions of the study protocol.
Exclusion Criteria:
- The patient has a decrease in the PANSS Total Score at Baseline compared with the Total Score at Screening.
- Patient who recently participated in another interventional clinical study with an Investigational Medicinal Product.
- The patient has uncontrolled abnormality which may impact the ability of the patient to participate or potentially confound the study results.
- The patient has a history of severe head injury, traumatic brain injury, myocardial infarction or stroke.
- The patient has a moderate or severe substance use disorder for alcohol or other substances of abuse except nicotine or caffeine.
- The patient is pregnant or lactating or intending to become pregnant or intending to donate ova.
- The patient has a history of or known personality disorder or other psychiatric disorder that, in the opinion of the Investigator, would interfere with participation in the study.
- The patient is considered by the Investigator to be at imminent risk of suicide or injury to self or others.
- The patient has chronic movement disorder that may interfere with the interpretation of study results.
- The patient has any existing or previous history of cancer or has newly diagnosed diabetes.
- The patient has long QT syndrome or is under treatment with antiarrhythmic drugs.
- The patient is considered to be treatment resistant. .
- The patient has received electroconvulsive therapy.
- The patient has any laboratory values outside the normal range that are considered by the Investigator to be clinically significant at Screening.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: CPL500036 low dose
Patients are to receive 20 mg of CPL500036 administered once dail for 28-days treatment period. |
CPL500036 is to be oral administered. Each patient is to take 2 capsules with active substance and 2 capsules of placebo daily. |
|
Sperimentale: CPL500036 high dose
Patients are to receive 40 mg of CPL500036 administered once dail for 28-days treatment period. |
CPL500036 is to be oral administered. Each patient is to take 4 capsules with active substance daily. |
|
Comparatore placebo: Placebo
Patients are to receive placebo administered once dail for 28-days treatment period. |
Placebo is to be oral administered. Each patient is to take 4 capsules of placebo daily. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change From Baseline in PANSS Positive Subscale at Week 4.
Lasso di tempo: Day -1, Week 4
|
The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression). The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112). Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia. |
Day -1, Week 4
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change From Baseline in PANSS Positive Subscale at Week 1, 2 and 3
Lasso di tempo: Day -1, Week 1, 2 and 3
|
The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression). The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112). Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia. |
Day -1, Week 1, 2 and 3
|
|
Change From Baseline in PANSS Total Score at Weeks 1, 2, 3, 4
Lasso di tempo: Day -1, Week 1, 2, 3 and 4
|
The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression). The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112). Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia. |
Day -1, Week 1, 2, 3 and 4
|
|
Change From Baseline in PANSS Subscales Using the Marder 5 Factor Model at Weeks 1, 2, 3, and 4
Lasso di tempo: Day -1, Week 1, 2, 3 and 4
|
The Positive and Negative Syndrom Scale (PANSS) Marder 5-Factor Model is a structure used for the Positive and Negative Syndrome Scale (as original PANSS scale), but breaking its 30 items (from positive, negative and general psychopathology groups) into five key symptom domains: Positive (8 items: Range 8-56), Negative (7 items: Range 7-49), Disorganized thoughts (7 items: Range 7-49), Uncontrolled hostility/excitement (4 items: Range 4-28), and Anxiety/depression (4 items: Range 4-28). The higher score in subscale, the more severe schizophrenia. |
Day -1, Week 1, 2, 3 and 4
|
|
Change From Baseline in PANSS Negative Subscales at Weeks 1, 2, 3 and 4
Lasso di tempo: Day -1, Week 1, 2, 3 and 4
|
The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression). The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112). Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia. |
Day -1, Week 1, 2, 3 and 4
|
|
Change From Baseline in PANSS General Psychopathology Subscale at Weeks 1, 2, 3 and 4
Lasso di tempo: Day -1, Week 1, 2, 3 and 4
|
The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression). The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112). Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia. |
Day -1, Week 1, 2, 3 and 4
|
|
Percentage of Clinical Responders Based on the PANSS Total Score.
Lasso di tempo: Day -1, Week 1, 2, 3 and 4
|
The Positive and Negative Syndrom Scale (PANSS) is a 30-item scale used to assessing schizophrenia symptoms, measuring positive (hallucinations, delusions), negative (social withdrawal, blunted affect), and general psychopathology (anxiety, depression). The scale include: 7 negative symptom items (with range score from 7 to 49), and 7 positive symptom items (with range score from 7 to 49), 16 general psychopathology symptom items (with score range from 16 to 112). Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient. The minimum total score is 30, the maximum total score is 210 points. Total score is obtained by summing the scores from all three subscales. The higher PANSS total score (and each subscale), the more severe schizophrenia. Clinical responder is defined as a ≥ 30% decrease from baseline. |
Day -1, Week 1, 2, 3 and 4
|
|
Change From Baseline in Clinical Global Impression Severity (CGI-S) Score at Weeks 1, 2, 3, and 4
Lasso di tempo: Day -1, Week 1, 2, 3 and 4
|
CGI-S scale is a physician-rated scale that is designed to rate the severity of the patient's illness at the time of assessment. It is a 7-point assessment where 1= normal (not at all ill) and 7 = among the most extremely ill patients. |
Day -1, Week 1, 2, 3 and 4
|
|
Clinical Global Impression Scale Improvement (CGI-I) Score at Weeks 1, 2, 3, 4.
Lasso di tempo: Day -1, Week 1, 2, 3 and 4
|
CGI-I is a 7 points scale that requires the clinician to assess how much the patient's illness has improved or worsened during treatment. It is a 7-point assessment where 1= Very much improved and 7 = Very much worse |
Day -1, Week 1, 2, 3 and 4
|
|
Percentage of Clinical Responders Based on the CGI-I Score.
Lasso di tempo: Day -1, Week 1, 2, 3 and 4
|
Day -1, Week 1, 2, 3 and 4
|
|
|
Change From Baseline in Brief Assessment of Cognition in Schizophrenia (BACS) T-Score at Weeks 2 and 4.
Lasso di tempo: Day -1, Week 2 and 4
|
Brief Assessment Cognition in Schizophrenia (BACS) is specifically designed to measure treatment-related improvements in cognition. A BACS T-score indicating cognitive performance of patients with schizophrenia with a mean of 50 and SD of 10, used for evaluating brain function. Scores are standardized, compared a person's with cognition impairment to a normative group, with scores below 50 indicating poorer performance (lower scores suggest greater difficulty) and above 50 better. |
Day -1, Week 2 and 4
|
|
Number of Abnormal Physical, Neurological, Ophthalmological and Dermatological Examination Findings.
Lasso di tempo: up to 6 weeks
|
up to 6 weeks
|
|
|
Number of Adverse Events.
Lasso di tempo: up to 6 weeks
|
All adverse events that occurence during study were assessed. |
up to 6 weeks
|
|
Number of Abnormal Clinically Significant Values in Vital Signs (Heart Rate, Blood Pressure, Respiratory Rate) Results.
Lasso di tempo: up to 6 weeks
|
up to 6 weeks
|
|
|
Number of Abnormal Clinically Significant Values in Laboratory Tests (Hematologic, Clinical Chemistry, Coagulation and Urinalysis) Results.
Lasso di tempo: up to 6 weeks
|
up to 6 weeks
|
|
|
Number of Abnormal Clinically Significant Findings in Electrocardiogram Results.
Lasso di tempo: up to 6 weeks
|
The following electrocardiogram parameters were assessed: PR interval, QRS interval, RR interval, QT interval and QTc interval. |
up to 6 weeks
|
|
Number and Intensity of Extrapyramidal Side Effects.
Lasso di tempo: up to 6 weeks
|
It was assessed by Extrapyramidal Symptom Rating Scale (ESRS). This scale is using to assess four types of drug-induced movement disorders (DIMD): Parkinsonism, akathisia, dystonia, and tardive dyskinesia. |
up to 6 weeks
|
Collaboratori e investigatori
Sponsor
Collaboratori
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 02PDE2019
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .